Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Biovision Ventures is a venture capital firm that focuses on early-stage investments in the life sciences and healthcare sectors. Founded with a mission to support innovative companies, Biovision Ventures operates from its headquarters in Luxembourg, with additional offices in Paphos, Cyprus, and Berlin, Germany. The firm has established a strong presence in the venture capital landscape, particularly in Europe and North America.
Currently, Biovision Ventures manages a portfolio that includes several notable companies and has participated in significant funding rounds. The firm emphasizes investments in companies that are developing novel therapeutic approaches and medical software solutions. With a team of two key members, including Managing Partner Alexey Konov, PhD, and Partner Igor Gonikhin, CFA, Biovision Ventures leverages its expertise to guide portfolio companies towards early value inflection points.
Over the years, Biovision Ventures has achieved notable milestones, including successful exits such as Retrosense Therapeutics and Bonti, both acquired by Allergan for substantial sums. The firm continues to seek out promising startups that align with its investment thesis, focusing on addressing unmet clinical needs through innovative solutions.
Biovision Ventures invests primarily in the life sciences sector, with a particular emphasis on therapeutics and Bio-IT solutions. The firm targets early-stage companies, specifically those in the Seed to Series B funding stages, where it can provide the most impactful support. Biovision Ventures is agnostic regarding specific diseases and modalities, allowing for a broad investment scope within the life sciences sector.
The firm prioritizes companies that possess strong intellectual property and are developing novel platform-based therapeutic approaches or medical software solutions for clinical use. This focus on addressing unmet clinical needs drives Biovision Ventures' investment strategy, as it seeks to translate scientific advancements into transformative therapies. The firm typically leads or co-leads investments, maintaining an active role in its portfolio companies, often taking board seats to provide guidance and support.
Biovision Ventures has built a notable portfolio of companies in the life sciences and healthcare sectors. Key portfolio companies include:
These companies exemplify Biovision Ventures' commitment to investing in high-potential startups that are addressing critical needs in the healthcare sector.
Alexey Konov, PhD: Managing Partner at Biovision Ventures, Alexey has a strong background in life sciences and venture capital. He has been involved in several successful investments, including Retrosense Therapeutics and Bonti, where he held board positions.
Igor Gonikhin, CFA: Partner at Biovision Ventures, Igor brings expertise in finance and investment strategy. He plays a key role in evaluating potential investments and supporting portfolio companies, including serving on the board of Hawthorne Health.
To pitch Biovision Ventures, founders should use the preferred channel available on their website at biovision.vc. It is essential to include a comprehensive deck that outlines the business model, market opportunity, and team qualifications. While there is no specific application form mentioned, a well-structured pitch deck is crucial.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial, as they can enhance the chances of securing a meeting with the firm.
In January 2026, Biovision Ventures participated in a Series B funding round for Diagonal Therapeutics, contributing to a total of $125 million raised. This marks one of the largest known rounds for the firm.
In October 2024, the firm invested $43 million in Arda Therapeutics during its Series A round, further expanding its portfolio in the life sciences sector.
Biovision Ventures also invested $13.4 million in Radar Therapeutics during its Seed round, showcasing its commitment to supporting early-stage companies.
What are Biovision Ventures' investment criteria?
Biovision Ventures focuses on early-stage life sciences and healthcare companies, particularly those developing therapeutics and Bio-IT solutions. The firm prioritizes companies with strong intellectual property and those addressing unmet clinical needs.
How can I apply or pitch to Biovision Ventures?
Founders can pitch their ideas through the firm's website at biovision.vc. It is advisable to include a detailed business plan and information about the team and technology.
What makes Biovision Ventures different from other VC firms?
Biovision Ventures distinguishes itself by its focus on early-stage investments in the life sciences sector and its hands-on approach to supporting portfolio companies, often taking board seats to guide them through critical growth phases.
What is the geographic scope of Biovision Ventures' investments?
The firm primarily invests in private companies located in North America and Europe, aiming to identify global technological leaders regardless of their location.
What is the typical check size for investments?
Biovision Ventures typically invests between EUR 1.5 million and EUR 3 million in its portfolio companies, focusing on early-stage funding rounds.
What is Biovision Ventures' post-investment involvement like?
The firm maintains an active role in its portfolio companies, often taking board positions to provide strategic guidance and support as they work towards early value inflection points.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.